home.aspx
 
. https://pharmaceutical.report/Resources/Whitepapers/5d6b7636-67e3-45e1-8506-8979a37a9cdd_NAS Supplement Whitepaper.pdf
whitepaper
SHARESHARESHARE
PHARMA R&D ANNUAL REVIEW 2019 SUPPLEMENT
Following on from our review of trends in the current pharmaceutical R&D pipeline, published in March 2019 this supplement takes a look at the industry’s success stories of 2018 – the drugs which were launched on to the market for the first time during the year. Our survey focuses exclusively on new active substances (NASs): new chemical or biological entities where the active ingredient had received no prior approval for human use. This will include vaccines with novel antigenic components. As such, this list represents a subset of all the first launches which Pharmaprojects reported during 2018, excluding the 67 new drug launches with reformulated or non-NAS moieties, or biosimilars. So, to continue our sports theme this year, we’ll be looking at the drugs which successfully crossed the finishing line, hit the bullseye, and lifted the trophy, to become part of pharma’s elite 2018 team. In pharma as in sport, it’s all about winning. Pharma DOWNLOAD